A Less Common Cause of Acute Hepatitis in Kidney Transplant Recipients: A Case Series

Transplant Proc. 2022 Jun;54(5):1278-1281. doi: 10.1016/j.transproceed.2022.03.037. Epub 2022 Jun 26.

Abstract

Background: Hepatitis E virus (HEV) is a cause of significant morbidity and mortality, representing an important global public health problem. Immunocompetent patients with acute hepatitis E can clear the infection spontaneously; however, in approximately two thirds of cases, immunosuppressed patients, such as kidney transplant (KT) recipients, fail to clear the HEV infection and develop chronic hepatitis.

Patients and methods: We report 3 cases of HEV infection in KT patients. Two presented only with laboratory abnormalities and elevated liver enzymes, and 1 presented with symptomatic disease motivating hospital admission. None was able to clear the infection spontaneously, and they were all treated with ribavirin, accompanied with reduction of immunosuppressive drugs. Adverse effects of the treatment were reported in 2 patients, and in 1 case, a dose reduction was necessary. All patients responded to the treatment and have no current evidence of active disease. No alterations of basal kidney function during or related to the treatment were registered.

Discussion: HEV screening in KT patients presenting with abnormal liver function of undetermined cause is fundamental, as it might have poorer outcomes in this specific population. The treatment with ribavirin seems to be safe and effective, although we must always be alert to potential side effects, maintaining a close follow-up of these patients.

MeSH terms

  • Acute Disease
  • Hepatitis E virus*
  • Hepatitis E* / diagnosis
  • Hepatitis E* / drug therapy
  • Humans
  • Kidney Transplantation* / adverse effects
  • Ribavirin / adverse effects
  • Transplant Recipients

Substances

  • Ribavirin